Back to Search Start Over

Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters

Authors :
Petra Hamerlik
Eva Løbner Lund
Kristoffer Vitting-Seerup
Elisabeth Anne Adanma Obara
Hans Skovgaard Poulsen
Jane Skjøth-Rasmussen
Henriette Pedersen
Julia S. Johansen
Kamilla E. Jensen
Camilla Bjørnbak Holst
Source :
Cell Cycle, article-version (VoR) Version of Record, Holst, C B, Pedersen, H, Obara, E A A, Vitting-Seerup, K, Jensen, K E, Skjøth-Rasmussen, J, Lund, E L, Poulsen, H S, Johansen, J S & Hamerlik, P 2021, ' Perspective : targeting VEGF-A and YKL-40 in glioblastoma–matter matters ', Cell Cycle, vol. 20, no. 7, pp. 702-715 . https://doi.org/10.1080/15384101.2021.1901037
Publication Year :
2021
Publisher :
Taylor & Francis, 2021.

Abstract

Glioblastomas (GBM) are heterogeneous highly vascular brain tumors exploiting the unique microenvironment in the brain to resist treatment and anti-tumor responses. Anti-angiogenic agents, immunotherapy, and targeted therapy have been studied extensively in GBM patients over a number of decades with minimal success. Despite maximal efforts, prognosis remains dismal with an overall survival of approximately 15 months. Bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) antibody, underwent accelerated approval by the U.S. Food and Drug Administration in 2009 for the treatment of recurrent GBM based on promising preclinical and early clinical studies. Unfortunately, subsequent clinical trials did not find overall survival benefit. Pursuing pleiotropic targets and leaning toward multitarget strategies may be a key to more effective therapeutic intervention in GBM, but preclinical evaluation requires careful consideration of model choices. In this study, we discuss bevacizumab resistance, dual targeting of pro-angiogenic modulators VEGF and YKL-40 in the context of brain tumor microenvironment, and how model choice impacts study conclusions and its translational significance.

Details

Language :
English
ISSN :
15514005 and 15384101
Volume :
20
Issue :
7
Database :
OpenAIRE
Journal :
Cell Cycle
Accession number :
edsair.doi.dedup.....455c7e1e0ae71ee8c04676ce6038a836